MML Investors Services LLC Buys Shares of 11,000 China Cord Blood Corporation (CO)
MML Investors Services LLC bought a new stake in shares of China Cord Blood Corporation (NYSE:CO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 11,000 shares of the medical research company’s stock, valued at approximately $104,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Parametrica Management Ltd purchased a new stake in China Cord Blood Corporation during the 2nd quarter valued at $149,000. Spark Investment Management LLC purchased a new stake in China Cord Blood Corporation during the 1st quarter valued at $204,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in China Cord Blood Corporation by 12.2% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 40,870 shares of the medical research company’s stock valued at $272,000 after buying an additional 4,442 shares during the last quarter. SG Americas Securities LLC purchased a new stake in China Cord Blood Corporation during the 2nd quarter valued at $948,000. Finally, Lazard Asset Management LLC purchased a new stake in China Cord Blood Corporation during the 2nd quarter valued at $2,316,000. Institutional investors and hedge funds own 13.33% of the company’s stock.
Shares of China Cord Blood Corporation (NYSE:CO) opened at 11.31 on Friday. The stock’s 50 day moving average is $12.26 and its 200-day moving average is $9.67. The company has a market cap of $1.28 billion, a P/E ratio of 36.13 and a beta of 0.88. China Cord Blood Corporation has a 12 month low of $4.27 and a 12 month high of $14.95.
China Cord Blood Corporation (NYSE:CO) last posted its quarterly earnings results on Wednesday, August 23rd. The medical research company reported $0.09 earnings per share (EPS) for the quarter. China Cord Blood Corporation had a net margin of 22.07% and a return on equity of 8.64%. The business had revenue of $33.07 million during the quarter. On average, equities analysts forecast that China Cord Blood Corporation will post $0.15 EPS for the current year.
Separately, BidaskClub upgraded shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 1st.
COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/mml-investors-services-llc-buys-shares-of-11000-china-cord-blood-corporation-co/1614785.html.
China Cord Blood Corporation Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.